Craig Walker, MD
Interventional Cardiology · Houma, LANPI 1548267529
Payments from drug & device makers
What this record shows
This record is dominated by other: $3,223,062 of the $5,010,759 with a category attached, or 64.3%. 60 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 48.6% of the total. Reporting peaked in 2021 at $3,250,213 and has fallen 96.5% since, to $115,150 in 2025. Among interventional cardiology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,352 payments — averaging $3706.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$2.4M
- Anika Therapeutics, Inc.$920K
- Cardiva Medical, Inc.$694K
- Johnson & Johnson$310K
- Philips North America LLC$182K
- Boehringer Ingelheim$74K
- plus $394K from 54 others
Across 171 payments — averaging $2755.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$91K
- Novartis$72K
- Abbott$69K
- Boston Scientific$63K
- Bard Peripheral Vascular, Inc.$56K
- Trireme Medical LLC$37K
- plus $84K from 7 others
Across 17 payments — averaging $4480.81 each. An ownership or investment interest held by the physician or an immediate family member.
- Vasorum USA Inc.$50K
- Centerline Biomedical Inc.$26K
- Cardiosolutions, Inc.$0
- Arthrosurface Incorporated$0
- Cardio Flow, Inc.$0
- Cardiva Medical, Inc.$0
What the payments were for
- Consulting fees$129,5543%
- Speaking & faculty fees$719,54014%
- Travel & lodging$75,2962%
- Food & beverage$50,9291%
- Education$650%
- Gifts$990%
- Ownership interest$812,21416%
- Other$3,223,06264%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cardiva VASCADE 6/7F VCS$647,917
- Cardiva VASCADE MVP VVCS 6-12F$638,466
- Cardiva VASCADE 5F VCS$637,989
- Cardiva Catalyst II VCS$637,989
- Cardiva Catalyst III VCS$637,989
- XARELTO$309,381
- JARDIANCE$86,071
- IGT D Peripheral$62,226
- (9520) IGT Devices Undivided$59,498
- Ozempic$56,892
- Vascular Closure Device$44,141
- Repatha$42,230
- Spectranetics Undiv$33,500
- Kerendia$29,792
- ASAHI PTCA Guide Wire$23,914
- NEXLIZET$20,458
- NEXLETOL$20,458
- Supera peripheral stent system$16,664
- S.M.A.R.T.$15,135
- Varithena Administration Pack$11,204
How this compares
$5,010,759 in reported general payments places this provider in the 95th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 191 | $202,080 |
| EliquisApixaban | 148 | $177,513 |
| XareltoRivaroxaban | 175 | $160,702 |
| Repatha SureclickEvolocumab | 176 | $119,397 |
| MounjaroTirzepatide | 54 | $61,045 |
| OzempicSemaglutide | 29 | $47,366 |
| Praluent PenAlirocumab | 49 | $25,611 |
| KerendiaFinerenone | 22 | $23,533 |
| BrilintaTicagrelor | 25 | $19,354 |
| EntrestoSacubitril/Valsartan | 12 | $13,325 |
| VascepaIcosapent Ethyl | 18 | $10,211 |
| Repatha PushtronexEvolocumab | 17 | $9,958 |
| FarxigaDapagliflozin Propanediol | 11 | $8,880 |
| ClopidogrelClopidogrel Bisulfate | 896 | $8,554 |
| Prasugrel Hcl | 71 | $6,857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $74,374 | $202,080191 claims |
| PfizerEliquis | $290 | $177,513148 claims |
| Johnson & JohnsonXarelto | $309,761 | $160,702175 claims |
| Lilly USA, LLCMounjaro | $12,317 | $61,04554 claims |
| Novo NordiskOzempic | $57,379 | $47,36629 claims |
| BayerKerendia | $34,670 | $23,53322 claims |
| NovartisEntresto | $3,305 | $13,32512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Houma
- Pradeep NairHouma$212K
- Richard AbbenHouma$101K
- Matthew FinnHouma$69K
- Anil ChagarlamudiHouma$27K
- Denzil MoraesBaton Rouge$901K
- Ankur LodhaLafayette$640K
- Rajan PatelNew Orleans$517K
- Agostino IngraldiLafayette$315K
- Steven BaileyShreveport$305K
- James JenkinsNew Orleans$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.